دورية أكاديمية
Clinical outcomes in elderly patients with advanced non-small cell lung cancer: results from ARIES, a bevacizumab observational cohort study.
| العنوان: | Clinical outcomes in elderly patients with advanced non-small cell lung cancer: results from ARIES, a bevacizumab observational cohort study. |
|---|---|
| المؤلفون: | Wozniak AJ; Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA. Electronic address: wozniakt@karmanos.org., Kosty MP; Scripps Clinic, La Jolla, CA, USA., Jahanzeb M; UM Sylvester Comprehensive Cancer Center, Miami, FL, USA., Brahmer JR; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA., Spigel DR; Sarah Cannon Research Institute, Nashville, TN, USA., Leon L; Genentech, Inc., South San Francisco, CA, USA., Fish S; Genentech, Inc., South San Francisco, CA, USA., Flick ED; Genentech, Inc., South San Francisco, CA, USA., Hazard SJ; Genentech, Inc., South San Francisco, CA, USA., Lynch TJ Jr; Yale Cancer Center and Smilow Cancer Hospital, New Haven, CT, USA. |
| المصدر: | Clinical oncology (Royal College of Radiologists (Great Britain)) [Clin Oncol (R Coll Radiol)] 2015 Apr; Vol. 27 (4), pp. 187-96. Date of Electronic Publication: 2015 Jan 07. |
| نوع المنشور: | Clinical Trial, Phase III; Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: W.B. Saunders Country of Publication: England NLM ID: 9002902 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1433-2981 (Electronic) Linking ISSN: 09366555 NLM ISO Abbreviation: Clin Oncol (R Coll Radiol) Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2003- : London : W.B. Saunders Original Publication: [London, UK] : Springer International, [c1989- |
| مواضيع طبية MeSH: | Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Carcinoma, Non-Small-Cell Lung/*drug therapy , Lung Neoplasms/*drug therapy, Adult ; Age Factors ; Aged ; Aged, 80 and over ; Bevacizumab/administration & dosage ; Cohort Studies ; Disease-Free Survival ; Female ; Humans ; Male ; Middle Aged ; Prospective Studies ; Retrospective Studies ; Treatment Outcome |
| مستخلص: | Aims: Retrospective analyses from first-line clinical studies in advanced non-small cell lung cancer (NSCLC) have reported conflicting results on progression-free survival (PFS) and overall survival benefits with the addition of bevacizumab to chemotherapy in elderly patients. Here we report effectiveness and safety outcomes by age subgroup for patients with NSCLC in the ARIES observational cohort study. Materials and Methods: ARIES enrolled patients with advanced non-squamous NSCLC who received first-line bevacizumab-containing treatment per physician's choice. Kaplan-Meier estimates were used to calculate medians and 95% confidence intervals for PFS and overall survival for patients aged <65, ≥65, <75 and ≥75 years. Results: In total, 1967 patients receiving first-line treatment with bevacizumab and chemotherapy were enrolled. The median PFS and overall survival values were 6.4 (95% confidence interval = 6.0-6.8) and 14.2 (95% confidence interval = 12.7-15.2) months for patients aged <65 years, respectively, and 6.8 (95% confidence interval = 6.3-7.0) and 12.1 (95% confidence interval = 11.4-13.1) months for patients ≥65 years, respectively. For patients <75 years, the median PFS and overall survival values were 6.6 (95% confidence interval = 6.3-6.9) and 13.5 (95% confidence interval = 12.6-14.5) months, respectively, and 6.6 (95% confidence interval = 5.9-7.1) and 11.6 (95% confidence interval = 10.0-12.5) months, respectively, for patients ≥75 years. Incidence proportions of bevacizumab-associated adverse events were generally similar across all age groups. Conclusions: Data from the ARIES study suggest that treatment with bevacizumab in combination with chemotherapy is a viable first-line treatment option for elderly bevacizumab-eligible patients with advanced non-squamous NSCLC. (Copyright © 2014 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Bevacizumab; NSCLC; chemotherapy; elderly; observational cohort study |
| سلسلة جزيئية: | ClinicalTrials.gov NCT00388206 |
| المشرفين على المادة: | 2S9ZZM9Q9V (Bevacizumab) |
| تواريخ الأحداث: | Date Created: 20150111 Date Completed: 20151125 Latest Revision: 20150309 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1016/j.clon.2014.12.002 |
| PMID: | 25576353 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1433-2981 |
|---|---|
| DOI: | 10.1016/j.clon.2014.12.002 |